XTX Topco’s Akebia Therapeutics AKBA Stock Holding History

XTX Topco’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$340K	Sell	244,453 -228,032	-48%	-$313K	0.01%	2377
2025 Q4	$761K	Buy	472,485 +434,284	+1,137%	+$909K	0.02%	1241
2025 Q3	$104K	Sell	38,201 -112,700	-75%	-$375K	0.01%	2015
2025 Q2	$549K	Buy	150,901 +104,890	+228%	+$288K	0.02%	1023
2025 Q1	$88.3K	Buy	+46,011	New	+$93.9K	﹤0.01%	1895
2024 Q4	–	Sell	-44,267	Closed	-$58.4K	–	2239
2024 Q3	$58.4K	Buy	+44,267	New	+$59.1K	﹤0.01%	1674
2024 Q1	–	Sell	-99,645	Closed	-$124K	–	1790
2023 Q4	$124K	Sell	99,645 -38,861	-28%	-$39.6K	0.03%	1086
2023 Q3	$158K	Sell	138,506 -200,861	-59%	-$258K	0.03%	1092
2023 Q2	$311K	Buy	+339,367	New	+$328K	0.06%	692
2022 Q2	–	Sell	-102,392	Closed	-$74K	–	823
2022 Q1	$74K	Buy	102,392 +75,635	+283%	+$162K	0.03%	552
2021 Q4	$60K	Buy	+26,757	New	+$73K	0.03%	544
2021 Q3	–	Sell	-20,589	Closed	-$78K	–	664
2021 Q2	$78K	Buy	+20,589	New	+$69.3K	0.03%	687

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

XTX Topco's AKBA Position: Q1 2026 in Review

XTX Topco reduced its Akebia Therapeutics (AKBA) stake by 48% in Q1 2026, selling an estimated $313K and leaving 244,453 shares worth $340K. The position accounts for 0.01% of the portfolio, ranked #2377.

XTX Topco first reported a position in AKBA in Q2 2021 and has held it in 12 quarters since. The position peaked at $761K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

XTX Topco held 244,453 shares of Akebia Therapeutics worth $340K as of Q1 2026.
XTX Topco sold 228,032 Akebia Therapeutics shares in Q1 2026, an estimated $313K.
Akebia Therapeutics made up 0.01% of XTX Topco's portfolio in Q1 2026, its #2377 holding.
XTX Topco first reported a position in Akebia Therapeutics in Q2 2021 and has held it in 12 quarters since.
XTX Topco's Akebia Therapeutics position peaked at $761K in Q4 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.